Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
An increasingly favorable regulatory environment and direct comparison with competitors are drawing renewed attention to Arcellx's progress in late-stage clinical development. We'll explore how improved regulatory sentiment for its CAR-T program shapes Arcellx's current investment narrative amid heightened analyst optimism. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. What Is Arcellx's Investment Narrative? To own Arcellx, belief in the company's ability to commercialize its lead CAR-T therapy, anitocabtagene autoleucel (anito-cel), for multiple myeloma is front and center. The recent analyst price target hike and favorable regulatory sentiment, triggered by changes at the FDA and strong mid-stage clinical data, renew focus on a c
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]Yahoo! Finance
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and ExpositionBusiness Wire
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 11/17/25 - Form 4
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- ACLX's page on the SEC website